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introduction
Primary bone tumours are rare, accounting for <0.2% of
malignant tumours registered at the EUROCARE database.
They have a relatively high incidence in children and
adolescents, but are still numerically outnumbered by benign
bone tumours, which clinically may have a similar
presentation. They are also frequently difficult to recognize as
malignant by clinicians, radiologists as well as pathologists and
this leads to major diagnostic difficulties in non-specialized
centres. One of the main recommendations of this guideline is
that all patients with a suspected primary malignant bone
tumour should be referred to a bone sarcoma reference centre
or an institution belonging to a specialized bone sarcoma
network before biopsy.
Primary bone tumours are considerably outnumbered by
metastases to the bone in older patients, which in some
instances might mimic the presentation of a primary bone
tumour. The presence of non-mechanical pain or night pain
around the knee of a person in this or indeed any age
group should cause concern and lead to further immediate
investigation. Swelling will only be present if the tumour
has progressed through the cortex and distended the periosteum.
background
A general overview of the histological types of primary
malignant bone tumour according to the World Health
Organization (WHO) classification is given in Table 1. Several
staging systems for bone tumours are in use; however, none of
them are perfect or generally accepted.
osteosarcoma
Osteosarcoma is the most frequent primary cancer of bone
(incidence: 0.2–0.03/100 000/year). The incidence is higher in
adolescents (0.8–1.1/100 000/year at age 15–19), where it
accounts for >10% of all solid cancers. The male–female ratio is
1.4:1. Osteosarcoma usually arises in the metaphysis of a long
bone, most commonly around the knee. Involvement of the
axial skeleton and craniofacial bones is primarily observed in
adults. Conventional osteosarcoma, a high-grade malignancy,
accounts for 80%–90% of all osteosarcomas. Its most frequent
subtypes are osteoblastic, chondroblastic and fibroblastic.
Other high-grade types are telangiectatic, small cell and high-
grade surface osteosarcoma. Low-grade central and parosteal
osteosarcoma are low-grade malignancies, while periosteal
osteosarcoma is an intermediate-grade chondroblastic
osteosarcoma. Risk factors for the occurrence of osteosarcoma
include previous radiation therapy, Paget’s disease of bone and
germ line abnormalities such as the Li–Fraumeni syndrome,
Werner syndrome, Rothmund–Thomson syndrome, Bloom
syndrome and hereditary retinoblastoma.
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Ewing sarcoma
Ewing sarcoma (ES) (including primitive neuroectodermal
tumour of bone) is the second most common primary malignant
bone cancer. It occurs most frequently in children and
adolescents, but is also seen in adults. The median age at diagnosis
is 15 years and there is a male predilection of 1.5/1. ES is
diagnosed in white Caucasians under the age of 25 at an incidence
of 0.3/100 000 per year, but it is very uncommon in the African
and Asian population. About 25% of patients have ES of the
pelvic bones, while 50% have extremity tumours. Also the ribs
and vertebral column are frequently affected. ES may involve any
bone and (less commonly in children) arise purely in soft tissues
chondrosarcoma
Chondrosarcoma is one of the most frequently occurring bone
sarcomas of adulthood. The incidence is 0.1/100 000 per year,
with the most common age being between 30 and 60 years and
the male–female ratio is 1. Most chondrosarcomas arise as
primary malignant tumours, and the majority are low grade
(grade I) rather than high-grade (grade II–III). Most
chondrosarcomas arise centrally in the diametaphyseal region
of long bones, but they can also develop in flat bones such as
pelvis, rib and scapula. High-grade chondrosarcoma frequently
arises in the axial skeleton and long bones. Chondrosarcomas
can arise in pre-existing benign lesions such as enchondroma
and osteochondroma. In these circumstances they are referred
to as secondary chondrosarcomas and secondary peripheral
chondrosarcomas, respectively. The majority of
chondrosarcomas are of the conventional subtype, but rarer
subtypes include mesenchymal and clear cell chondrosarcoma.
In rare circumstances conventional chondrosarcomas can
‘dedifferentiate’ into a very high-grade tumour with a dismal
prognosis, so-called dedifferentiated chondrosarcoma. Most
chondrosarcomas are solitary, but they can occur as multiple
lesions in patients with multiple osteochondromas and
enchondromatosis.
spindle cell sarcomas of bone
Spindle cell sarcomas of bone (e.g. malignant fibrous
histiocytoma/fibrosarcoma of bone) comprise a diagnostically
heterogeneous group of malignant tumours including
fibrosarcoma (FS), malignant fibrous histiocytoma (MFH),
leiomyosarcoma and undifferentiated sarcoma. They arise in
a similar age group to chondrosarcoma but the skeletal
distribution is more like osteosarcoma. They typically present
with pain and have a high incidence of fracture at presentation.
They represent between 2% and 5% of primary bone
malignancies. The true incidence is hard to establish as the two
entities (MFH/FS) exhibit a significant degree of morphological
overlap, also reflected by an inconsistent use of terminology.
Males are more frequently affected than females. An association
with pre-existing disease (Paget’s disease or bone infarct) or
history of previous irradiation has been reported. It is not
unusual for a spindle cell sarcoma to be found to be either
a dedifferentiated chondrosarcoma or osteosarcoma after
examining different sections of the resection.
other bone sarcomas
These include such entities as adamantinoma and chordoma,
malignancy in giant cell tumour, angiosarcoma and liposarcoma,
that have specific clinical presentations and management.
clinical presentation
The medical history should focus on symptoms such as duration,
intensity and timing of complaints, for example night pain or
fracture. Moreover, specific events for bone tumours include
prior benign/malignant lesions, family history and previous
radiotherapy. A recent injury does not rule out a malignant
tumour and must not prevent appropriate diagnostic
procedures. All patients should have a full physical examination.
Specific attention should be given to the size, consistency of the
swelling, its location and mobility, the relation of swelling to the
involved bone and the presence of regional/local lymph nodes.
imaging
The likely diagnosis of a suspected bone tumour is related to
age. Before 5 years of age, a destructive bone lesion is most
Table 1. 2002 WHO classification of malignant bone tumours
Osteogenic tumours Osteosarcoma 9180/3
Conventional 9180/3
Chondroblastic 9181/3
Fibroblastic 9182/3
Osteoblastic 9180/3
Telangiectatic 9183/3
Small cell 9185/3
Low-grade central 9187/3
Secondary 9180/3
Parosteal 9192/3
Periosteal 9193/3
High-grade surface 9194/3
Ewing sarcoma/primitive
neuroectodermal tumour
Ewing sarcoma 9260/3
Cartilage Chondrosarcoma 9220/3
Central, primary, and
secondary
9220/3
Peripheral 9221/3
Dedifferentiated 9243/3
Mesenchymal 9240/3
Clear cell 9242/3
Fibrogenic tumours Fibrosarcoma 8810/3
Fibrohistiocytic tumours Malignant fibrous
histiocytoma
8830/3
Haematopoietic tumours Plasma cell myeloma 9732/3
Malignant lymphoma, NOS 9590/3
Giant cell tumour Malignancy in giant cell
tumour
9250/3
Notochordal tumours Chordoma 9370/3
Vascular tumours Angiosarcoma 9120/3
Smooth muscle tumours Leiomyosarcoma 8890/3
Lipogenic tumours Liposarcoma 8850/3
Miscellaneous tumours Adamantinoma 9261/3
Although listed by the WHO as bone tumours, plasma cell myeloma, as well
as primary malignant lymphoma of bone are not dealt with by these
guidelines.
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commonly metastatic neuroblastoma or eosinophilic
granuloma; >5 years, it is often a primary bone sarcoma; >40
years of age, it tends to be metastasis or myeloma.
diagnosis and local staging
Conventional radiographs in two planes should always be the
first investigation. CT should only be used in the case of
a diagnostic problem or doubt, to visualize more clearly
calcification, periosteal bone formation, cortical destruction or
soft tissue involvement. When the diagnosis of malignancy
cannot be excluded with certainty on radiographs, the next
imaging step is MRI of the whole bone with adjacent joints,
which is the best modality for local staging.
General staging should be carried out to assess the extent of
distant disease including bone scintigraphy and chest
radiographs and CT; small nodules are not specific for
malignancy. Whole body MRI and PET are under evaluation
for both staging and treatment response evaluation. Additional
appropriate imaging studies and biopsies should be taken from
suspicious sites, as the exact staging of the disease has an impact
on treatment and outcome [III, B].
In the case of chondrosarcoma contrast-enhanced MRI can
reveal high-grade areas: this provides a useful guide to the
site of biopsy.
biopsy
The biopsy of a suspected primary malignant bone tumour
should be carried out at the reference centre, by the surgeon
who is to carry out the definitive tumour resection,
a radiologist, or a member of the team. The principles of the
biopsy are:
 there should be minimal contamination of normal tissues;
 in many situations core needle biopsy will be more than
adequate, often controlled by ultrasound, X-ray or CT;
 samples should preferably be taken for microbiological
culture as well as histology;
 in the tumour centre samples should be snap-frozen for
future studies;
 samples must be interpreted by an experienced pathologist;
 the request form should contain sufficient detail for the
pathologist including the site of the tumour, the patient’s age
and the radiological differential diagnosis.
It is advised in the case of tumours and tumour-simulating lesions
of the skeleton, to determine the staging of the lesion before the
biopsy. An important advantage of staging studies obtained before
the biopsy is the possibility of choosing the location of the biopsy,
taking into account possible future surgery, especially when it
concerns limb salvage surgery. Imaging studies can also indicate
the most representative part of the lesion. Core needle biopsy
(multiple) (for example Jamshidi, but not fine-needle
aspiration) or open biopsy (depending on the location of the
lesion and local expertise, difficult cases) is preferred. An
excision biopsy is contraindicated for all cases that present the
possibility of an aggressive–benign or malignant lesion,
because an excision without oncologically adequate margins
will contaminate more tissue compartments than necessary. If
an open biopsy is done, it should be performed using
a longitudinal incision. To be sure that the biopsy location is
adequate and the tissue is representative for the resulting
process, it is recommended that X-rays be taken of the biopsy
location and the pathologist consulted directly (by frozen
section) after taking the biopsy in case more material is
required. In aggressive and malignant tumours of bone, the
biopsy tract should be considered to be contaminated with
tumour and must be removed together with the resection
specimen to avoid local recurrences, including the possible
channels through which drains have been placed. Biopsy tracts
should be clearly marked by means of a small incision or ink
tattoo to ensure that the location can be recognized at the
definitive procedure.
In cases of spinal column involvement, laminectomy or
decompression should be avoided unless necessary to relieve
spinal cord compression.
general comment on tumour handling. Material should be
quickly, ideally within half an hour, submitted for pathological
assessment; upon arrival, and before formalin fixation, tumour
imprints (touch preps) can be taken (useful for tumour-specific
translocation by FISH), and tissue/cell suspensions should be
kept frozen in cryomoulds. A further option is to establish
primary cell cultures for cytogenetics. Tumour banks are useful
for diagnosis and translational research into the molecular
pathology of cancer; therefore informed consent for tumour
banking should be sought that allows for later analysis and
research according to local practice.
reporting pathology
The nature of the bone specimen received for pathology
reporting should be recorded, i.e. needle biopsy, curettage,
excision (e.g. segmental resection, limb salvage amputation or
other complex resection, such as a hemipelvectomy). It is usually
necessary to decalcify a bone tumour biopsy. The pathologist
should receive information regarding the clinical/radiological
context in which the tumour has arisen, relevant observations
made at the time of surgery and whether the patient has received
preoperative chemotherapy. The size (measured in three
dimensions inmm) of the tumour in the resected bone should be
noted. The histological features of the tumour should be
described and the tumour type (and subtype) specified according
to the latest WHO criteria. The extent of tumour necrosis in
response to preoperative therapy should be assessed as being
more or less than 90%necrosis. The pathology report should note
the extent of local tumour spread, including involvement of
specific anatomical compartments. Whether the resection
margins are clear or involved by tumour should be noted and the
distance (in mm) of tumour from the nearest resection margin
measured. The results of relevant ancillary investigations (e.g.
immunohistochemistry) should be recorded. The tumour should
be classified using SNOMED or ICD-0 codes.
staging and risk assessment
Ideally all cases of suspected bone tumour should be discussed
at a multidisciplinary team meeting that includes the
clinical practice guidelines Annals of Oncology
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radiologist who has interpreted the imaging and the pathologist
who has reviewed the biopsy material and the surgeon and
oncologist undertaking treatment. This will minimize the risk
of errors in diagnosis, staging, risk assessment and treatment.
laboratory tests
No specific laboratory tests for the diagnosis of bone sarcoma
are available. However, some are useful in the follow-up in
Ewing sarcoma and osteosarcoma and may also be of
prognostic value, such as alkaline phosphatase (AP) and lactate
dehydrogenase (LDH).
osteosarcoma. Staging: 75% of all osteosarcomas arise around
the knee. Typically there is pain, which begins insidiously and
gradually becomes constant; pain may be present at night and is
often non-mechanical in nature. Localized swelling and
limitation of joint movement are later findings.
Risk assessment: adverse prognostic or predictive factors
include detectable primary metastases, poor histological
response to preoperative chemotherapy, axial or proximal
extremity tumour site, large tumour volume, elevated serum
AP or LDH, and older age [III, B]. Staging should include local
imaging studies, as outlined below.
Ewing sarcoma. Staging and molecular pathology: ES is a small
blue round-cell tumour, PAS+ and CD99 (MIC2) positive. All
ESs are high-grade tumours. The definitive diagnosis is made
by biopsy, providing sufficient material for conventional
histology, immunohistochemistry, molecular pathology and
biobanking (fresh, unfixed material). Molecular biology studies
have shown that all these tumours share a common gene
rearrangement involving the EWS gene on chromosome 22. In
most cases, this involves a reciprocal translocation
t(11;22)(q24;q12), but t(21;22)(q22;q12) and others may also
occur [t(7;22), t(17;22) and t(2;22) translocations and inv(22)].
Although most Ewing sarcoma can be recognized with classical
haematoxylin–eosin (H&E) and immunohistochemistry,
including CD99, EWS translocation detection is mandatory
when the clinical–pathological presentation is unusual, or the
histological diagnosis is doubtful [II, B]. A reference laboratory
for Ewing sarcoma diagnosis should have both FISH and RT–
PCR available. The laboratory is strongly recommended to be
enrolled in an external quality assurance programme. RT–PCR
is the investigation of choice when frozen tissue is available, and
FISH is a good choice when only formalin-fixed paraffin-
embedded tissue or touch preps (imprints) are available. There
are several commercial sources for EWS break-apart probes.
Assays using EWS break-apart probes do not detect EWS–FLI1
fusions, but only EWS rearrangements, which should not be
a problem when interpreted in the appropriate clinical and
pathological context.
Some staging practices such as light microscopic analysis of
bone marrow aspirates, and biopsies from sites distal to the
lesion (metastases) are mandatory. The use of RT–PCR of bone
marrow aspirate (metastases) is under investigation. The added
value in prognostic sense over light microscopic evaluation has
not been proved yet [IV, C].
Cytogenetic analysis by chromosome banding applying
Multicolour FISH/Spectral FISH can be helpful to detect
multichromosomal rearrangements in cases in which more
conventional molecular techniques (FISH, RT–PCR) cannot
help to get to the diagnosis.
Risk assessment: between 20% and 25% of patients are
diagnosed with metastatic disease (10% lung, 10% bones/bone
marrow, 5% combinations or others). Staging must be oriented
to detect lung, bone and bone marrow metastases. All patients
should have a bone marrow biopsy and aspirate performed
before starting treatment. PCR techniques to investigate for
bone marrow metastases are currently under evaluation. Bone
metastases confer a poorer outcome than lung/pleura
metastases (<20% compared with 20%–40% 5- year survival).
Other known prognostic factors are tumour size or volume,
serum LDH levels, axial localization or older age (>15 years). A
poor histological response to preoperative chemotherapy, and
incomplete or no surgery for local therapy are further adverse
prognostic factors [II, B].
chondrosarcoma. Staging: most chondrosarcomas present with
a painless mass. Pain at the site of a cartilaginous lesion may be
an indicator of malignancy.
Risk assessment: the differentiation between benign
enchondroma or osteochondroma and malignant grade I
chondrosarcoma can be difficult. In the phalanges of the hands
and feet malignancy is extremely rare, but in the other long
bones central cartilaginous lesions should be considered
low-grade chondrosarcoma till proved otherwise. Inoperable,
locally advanced and metastatic high-grade chondrosarcomas
have a poor prognosis because of resistance to conventional
treatments such as radiotherapy and chemotherapy. Prognosis
depends on histological grade. However, histological
classification is subject to variability in interpretation, with
grade II and III chondrosarcomas often grouped together even
though there is a wide spectrum of outcome. Also grade I
tumours do not have 100% survival, mainly due to problematic
local recurrence or progression into high grade upon
occurrence. In particular, dedifferentiated chondrosarcomas are
aggressive and frequently metastasize.
spindle cell sarcomas of bone (MFH/FS). Spindle cell sarcomas
typically present in an older patient with a lytic lesion in bone. In
many the differential diagnosis will be a metastasis. Full staging
and biopsy are required to reach a diagnosis. Pathological
fractures are common and should be investigated before fixation.
treatment
prevention and management of pathological
fracture
In the case of an existing pathological fracture in a possible
primary malignant bone tumour, adequate imaging should be
performed including MRI followed by biopsy. A pathological
fracture may lead to dissemination of tumour cells into
surrounding tissues and increase the risk of local recurrence.
Thus in patients with weakened bone apparent at presentation
there may be a strong case for immobilizing the part following
the biopsy, usually by application of an external splint. In the
case of an existing pathological fracture in a possible primary
malignant bone tumour, adequate imaging should be performed
Annals of Oncology clinical practice guidelines
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including MRI followed by biopsy. In cases of fracture, internal
fixation is contraindicated as it disseminates tumour further into
both bone and soft tissues and increases the risk of local
recurrence. External splintage is recommended, along with
appropriate pain control. Neoadjuvant chemotherapy should be
used in the expectation that a good response will allow the
fracture haematoma to contract and allow subsequent resection
of the tumour and the involved soft tissues. In patients with
a poor response to chemotherapy or in tumours unlikely to
respond to chemotherapy then early surgery obtaining wide
margins should be considered; in some cases this may require
amputation. Postoperative radiotherapy may be considered to
try to decrease the risk of local recurrence in radioresponsive
tumours. Resection could be considered if feasible.
systemic therapy
As malignant primary bone tumours are rare cancers, and as
management is complex, the accepted standard is treatment
either in reference centres or within reference networks able to
provide access to the full spectrum of care or shared with such
centres within reference networks [IV, A]. There, therapy is
usually given within the framework of prospective, often
collaborative, clinical studies, or established treatment
protocols. In the case of high-grade osteosarcoma, Ewing
sarcoma or spindle cell sarcoma, following biopsy-proven
diagnosis primary chemotherapy is indicated, preferably within
the framework of (inter)national trials.
baseline assessments. Chemotherapy treatment can result in
renal, cardiac and auditory dysfunction, and patients
undergoing this treatment must have baseline renal function
testing and assessment of cardiac function as well as an
audiogram (in the case of treatment with platinum derivates).
Sperm storage is recommended for male patients of
reproductive age. For female patients: consult fertility physician
for available options (usually investigational) and if available
discuss with the patient.
treatment evaluation by imaging
osteosarcoma. Changes in the size and ossification of the
tumour are not reliable criteria of tumour response to
neoadjuvant chemotherapy. Assessment of MRI peritumoral
oedema is helpful: its disappearance is a sign of good treatment
response. Dynamic MRI is reliable, but requires sequential
scans to evaluate change in tumour vascularity. Assessment of
response is usually only apparent after several cycles of
chemotherapy. It is therefore useful in rare difficult cases to
plan surgery, but not to change early a chemotherapy regimen.
Ewing sarcoma. Change in the size of the soft tissue mass is
easily evaluated on MRI, and is a rather reliable indicator of
tumour response. Dynamic MRI is not as reliable as in
osteosarcoma, as remaining small tumour foci may not be
detected. Sequential FDG-PET evaluation might be of
additional value.
surgery
Surgery should be performed only after adequate preoperative
staging and—depending on the tumour entity—primary
chemotherapy, striving to obtain adequate surgical margins as
narrower margins are associated with an increased risk of local
recurrence. If possible a wide en-bloc resection should be
performed, in general intracompartmental, but in the case of
clear indications (easily removable bone, muscle) the entire
bone/muscle compartment (extracompartmental) can be
removed. One should consider the consequences for the
remaining usefulness of the limb when obtaining wide tumour-
free margins [III, B].
In the case of an indication for postoperative radiotherapy
during surgery the risk areas and marginal margins should be
identifiedwith titanium(MRI-inert)haemo-clips.Areas suspicious
for close margins should also be marked on the surgical specimen
sent to pathology. The type of surgical reconstruction will depend
on patient and surgeon choice and experience following open
discussion of the risks and benefits of different options.
requirements for the surgical report. Describe the entire
procedure, including the approach, relation to vital structures
(vessels, nerves) resection margins, anatomical proportions
(draw resection), risk areas (marginal borders) in relation to
the resection specimen. Describe the placement of haemo-clips
on the risk areas and vital structures, related to the wound area,
give proportions in centimetres and describe the
reconstruction. Questions to the pathologist related to the
resection specimen: does the diagnosis from the resection
specimen confirm the diagnosis of the biopsy? Can the surgery
be considered a success based on the resection margin (risk
locations marked by the surgeon)? Special attention should be
given to the different compartments bone, nerves, muscle,
joint, growth plate cartilage vessels, etc.
radiotherapy
The role of radiotherapy in osteosarcoma and chondrosarcoma
is limited but may be appropriate in highly selected cases or for
palliation [IV, C]. Further boost techniques to increase the local
dose may be considered in osteosarcoma, including intensity-
modulated radiotherapy (IMRT), proton therapy or samarium.
Excellent outcomes have been reported for skull base
chondrosarcomas with proton beam radiotherapy achieving
80%–90% local control rates.
Ewing sarcoma is a radiation-responsive tumour.
Radiotherapy can, in combination with chemotherapy, achieve
local control, but complete surgery when feasible has to be
regarded as the first choice of local therapy. Incomplete surgery,
even when combined with postoperative radiotherapy, is not
superior to radiotherapy alone and should be avoided. If,
however, incomplete surgery has occurred, it should be
followed by postoperative radiotherapy.
specific treatment recommendations
osteosarcoma
localized disease. Curative treatment for high-grade
osteosarcoma consists of surgery and chemotherapy [I, A].
Compared with surgery alone, multimodal treatment of high-
grade osteosarcoma increases disease-free survival probabilities
from only 10%–20% to >60%.
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The goal of surgery is to safely remove the tumour and yet
preserve as much function as possible. Most patients should be
considered candidates for limb salvage. Doxorubicin, cisplatin,
high-dose methotrexate and ifosfamide have antitumor activity
in osteosarcoma [I, A]. These drugs should be administered
with adequate supportive care by experienced paediatric
oncologists or medical oncologists in reference institutions with
appropriate infrastructure with a multidisciplinary treatment
approach. Doxorubicin and cisplatin are frequently used as the
basis of treatment, and there is evidence that combinations with
methotrexate and/or ifosfamide might provide additional
benefit over two-drug schedules [II, A]. A variety of pre- and
postoperative combinations are used in common practice and
in clinical trials, and the ideal combination scheme and the
optimal treatment duration are yet to be defined. Most current
protocols include a period of preoperative chemotherapy,
although this has not been proven to add survival benefit over
postoperative chemotherapy alone [I, B]. Treatment is
commonly given over periods of 6–12 months. Current
prospective trials evaluate whether altering postoperative
chemotherapy in poor responders to preoperative systemic
therapy improves outcome of treatment. The use of
haematopoietic growth factors has not consistently resulted in
improved survival of osteosarcoma patients. The immune
modulator muramyl tripeptide added to postoperative
chemotherapy was associated with a statistically significant
advantage in overall survival and a non-significant trend in
event-free survival in one large randomized trial [II, B].
Muramyl tripeptide has been approved in Europe for
patients <30 years of age with completely resected localized
osteosarcoma, but has not been implemented in ongoing
prospective clinical trials in Europe. Whenever possible,
patients with osteosarcoma should receive chemotherapy in
the context of prospective trials, which is regarded as standard
of care.
The extent of histological response to preoperative
chemotherapy, however, offers important prognostic
information [I, A]. The multimodal treatment principles
detailed above were generated in children, adolescents and
young adults with high-grade central osteosarcoma, but also
relate to adults at least up to the age of 60 [III, B] and to rarer
variants of high-grade osteosarcoma, such as high-grade
surface, secondary [III, B]. Chemotherapy is also recommended
for older patients with osteosarcoma using adapted protocols.
Extraosseous osteosarcoma may be treated according to the
regimens of high-grade soft tissue sarcomas or osteosarcoma
schedules. There is no consensus on this point amongst experts.
Low-grade central and parosteal osteosarcoma are variants with
lower malignant potential, which are treated by surgery only
[III, B]. Careful analysis of the resected tumour may show areas
of high-grade change in which case the patient should be
treated as for a conventional osteosarcoma. The exact role of
chemotherapy has not been defined for periosteal and jaw
osteosarcoma.
metastatic disease and recurrent disease. Primary metastatic
osteosarcoma patients are treated with curative intent along the
principals of non-metastatic osteosarcomas. There are subsets
of patients who can have a very similar or even identical
prognosis to that of localized disease, with the mandatory
addition of surgical removal of all known metastatic deposits
[III, B], usually by exploratory thoracotomy including
palpation of the lung. Approximately 30% of all patients with
primary metastatic osteosarcoma and >40% of those who
achieve a complete surgical remission become long-term
survivors.
The management of recurrent osteosarcoma needs to take
into account the timing of recurrence/metastases, number of
metastases, site of metastases. Treatment for recurrent
osteosarcoma is primarily surgical. Prognosis is poor, with
long-term post-relapse survival <20%. Complete removal of all
metastases must be attempted [III, B], as the disease is
otherwise almost universally fatal, while more than a third of
patients with a second surgical remission survive for >5 years.
Even patients with multiple recurrences may be cured as long as
recurrences are resectable, and repeated thoracotomies are
often warranted [III, B]. CT scan can both overestimate and
underestimate the number of metastases.
The role of second-line chemotherapy for recurrent
osteosarcoma is much less well defined than that of surgery and
there is no accepted standard regimen. Choice may take into
account the prior disease-free interval, and often includes
ifosfamide 6 etoposide 6 carboplatin, etc. In the two largest
reported series, the use of second-line chemotherapy correlated
with limited prolongation of survival in patients with
inoperable metastatic recurrences, while a positive correlation
in operable disease was observed in only one of the two.
Ewing sarcoma
localized disease. With surgery or radiotherapy alone, 5-year
survival is <10%. With treatment in current multimodality
trials including chemotherapy, survival is 60%–70% in
localized and 20%–40% in metastatic disease.
All current trials employ three to six cycles of initial
chemotherapy after biopsy, followed by local therapy and
another six to ten cycles of chemotherapy usually applied at 3-
week intervals. Treatment duration is thus 10–12 months.
Agents considered most active include doxorubicin,
cyclophosphamide, ifosfamide, vincristine, dactinomycin and
etoposide. Virtually all active protocols are based on four- to
six-drug combinations of these substances [I, A].
Chemotherapy intensity is positively associated with outcome.
High-dose chemotherapy with blood stem cell transplantation
is still investigational in high-risk localized Ewing sarcoma.
Despite lively debate, complete surgery, where feasible, is
regarded as the best modality of local control given the higher
risk of local recurrence when radiotherapy is used as sole
treatment for the primary tumour. Radiotherapy alone should
be applied if complete surgery is impossible. Postoperative
radiotherapy should be given in cases of inadequate surgical
margins and discussed where histological response in the
surgical specimen was poor (i.e. >10% viable tumour cells) [IV,
C]. Intralesional surgery must be avoided as in one large series
it was found that this was of no benefit when compared with
radiotherapy alone. Treatment of adult patients follows the
same principles. However, tolerability of therapies in adults
needs to be taken into account when transferring treatment
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protocols conceived for children and patients of age £30–40
years. Treatment of patients with extraskeletal Ewing sarcoma
follows the same principles as for bone Ewing sarcoma.
metastatic and recurrent disease. Patients with metastases at
diagnosis treated with the same treatment approach as patients
with localized disease have a worse prognosis. Several non-
randomized trials have assessed the value of more intensive,
time-compressed or high-dose chemotherapy approaches,
followed by autologous stem cell rescue, with promising results
but evidence of benefit, resulting from trials, is pending [III, B].
In patients with lung metastases, whole lung irradiation may
confer a survival advantage [III, B]. The role of surgical
resection of residual metastases is less well defined. Patients
with bone or bone marrow metastases and patients
with recurrent disease still fare poorly, with 5-year survival
rates of 20%.
The only prognostic factor identified in relapse seems to be
time to relapse: patients relapsing later than 2 years from
initial diagnosis have a better outcome [III, B]. Doxorubicin
therapy is usually no longer feasible due to previously
achieved cumulative doses. Chemotherapy regimens in
relapse situations are not standardized and are commonly
based on alkylating agents (cyclophosphamide, high-dose
ifosfamide) in combination with topoisomerase inhibitors
(etoposide, topotecan) or irinotecan with temozolomide
[III, B].
chondrosarcoma
Assessing the grade of chondrosarcoma is difficult and
variations in opinion, even among experts, are common. Low-
grade cartilage tumours are unlikely to metastasize but may
recur locally. Grade I central chondrosarcomas in the long
bones of the limbs can be managed by curettage with or
without adjuvant (e.g. phenol, cement, cryotherapy) with
a high chance of success. Low-grade peripheral
chondrosarcomas (arising from osteochondromas) should be
surgically excised, aiming to excise the tumour with a covering
of normal tissue over it. Higher-grade chondrosarcomas
(including clear cell chondrosarcoma) and all chondrosarcomas
of the pelvis or axial skeleton should be surgically excised with
wide margins. Recent evidence suggests that mesenchymal
chondrosarcoma may be chemotherapy sensitive, and may be
considered for adjuvant or neoadjuvant therapy. There remains
uncertainty about chemotherapy sensitivity of dedifferentiated
chondrosarcoma but it is often treated like osteosarcoma,
with poorer outcome. There is a very high risk of local
recurrence following excision of dedifferentiated
chondrosarcoma, particularly in the presence of a pathological
fracture. If wide margins cannot be reliably achieved with limb
salvage then amputation should be considered.
Chondrosarcomas in the skull are often not resectable. On these
occasions proton beam radiotherapy could be considered
following debulking.
spindle cell sarcomas of bone (MFH/FS) treatment
Treatment strategies mimic those of osteosarcoma, with
chemotherapy and complete en-bloc resection including any
soft tissue component.
treatment of other bone tumours
Chordomas are rare, arising with an incidence of 0.5/million
population per year. They typically arise in the sacrum or base
of the skull recapitulating histologically notochord remnants.
Although conventional therapy has in the past been used to
complete surgical resection, there are now encouraging results
from high-dose radiotherapy using proton beams or carbon ion
facilities. Assessment in a specialist centre with expertise in
managing these tumours is essential to define the role of
surgery and/or radiotherapy. Metastases are rare but local
recurrence common. There is evidence of some effectiveness of
molecular targeted agents.
Adamantinoma of bone typically arises in the anterior cortex
of the diaphysis of the tibia. The osteofibrous dysplasia-like
subtype is low grade but will recur if not completely resected.
The other subtypes have a propensity to metastasize in
a substantial amount of cases, typically becoming clinically
evident after a prolonged period of time.
follow-up
Follow-up is designed to detect either local recurrence or
metastatic disease at a time when early treatment is still possible
and might be effective. Follow-up of high-grade tumours
should include both a physical examination of the tumour site
and assessment of the function and possible complications of
any reconstruction. Local imaging and chest X-ray/CT should
be the norm. Recommended intervals for follow-up after
completion of chemotherapy are every 6 weeks to 3 months for
the first 2 years; every 2–4 months for years 3–4; every 6
months for years 5–10 and thereafter every 6–12 months
according to local practice.
In the case of low-grade bone sarcoma the frequency of
follow-up visits may be less and may be 6 months for 2 years
and then annually. Late metastases as well as local recurrences
and functional deficits may occur >10 years after diagnosis and
there is no universally accepted stopping point for tumour
surveillance.
In Ewing sarcoma, where osseous metastases are likely,
isotope bone scanning can be used in addition. More recent
techniques (e.g. PET or whole body MRI) require further
evaluation.
It is important to evaluate the long-term toxicity effect of
chemotherapy and radiotherapy if appropriate. Monitoring for
late effect should be undertaken for >10 years after treatment,
depending on the chemotherapy protocol and radiation used
and in conjunction with late-effects services when available.
Secondary cancers may arise in survivors of bone sarcomas,
either related to or independent of irradiation. Secondary
leukaemia, particularly acute myeloid leukaemia, may rarely be
observed following chemotherapy as early as 2–5 years after
treatment [III, B].
notes
Levels of Evidence [I–V] and Grades of Recommendation [A–
D] as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
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considered justified standard clinical practice by the experts and
the ESMO faculty.
These Clinical Practice Guidelines have been developed
following a consensus process based on a consensus event
organized by ESMO in Lugano in November 2009. This
involved experts from the community of the European
sarcoma research groups, sarcoma networks of excellence and
ESMO Faculty. The names of the Writing Committee and the
Consensus Panel are indicated hereafter. The text reflects an
overall consensus among them, although each of them may
not necessarily find it consistent with his/her own views. The
EU-funded network of excellence CONTICANET
(CONnective TIssue CAncers NETwork) and EUROBONET
(EUROpean BOne NETwork) also supported financially the
consensus process.
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